MedCity News November 21, 2024
New advancements can only be fully realized when clinicians, lawmakers, and patients come together. Biomarker tests not only have the potential to improve patient outcomes and address health equity, they can also decrease expenses for financially vulnerable medical systems.
In the U.S., maternal mortality rates exceed most other developed countries, and a blood pressure pregnancy disorder called preeclampsia is one of the main contributors to this unfortunate statistic. Preeclampsia not only threatens the health of mothers and their babies during pregnancy, but it also increases the risk of cardiovascular disease for affected women later in life. For years, clinicians have sought to improve the clinical management of this disease; fortunately, a blood-based biomarker test that was designed to meet...
Today's Sponsors
Today's Sponsor